> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Increased Covid Risk For Those on Evusheld: FDA
- URL: https://www.fdaweb.com/increased-covid-risk-for-those-on-evusheld-fda/
- Published: 2022-10-03T12:00:00.000Z
- Updated: 2026-09-14T18:01:34.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152875

FDA has added important information to the emergency authorization of AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) to inform health care providers and individuals about the increased risk for developing Covid-19 when exposed to variants of SARS-CoV-2 that are not neutralized by Evusheld. The [agency says](https://www.fda.gov/drugs/drug-safety-and-availability/fda-releases-important-information-about-risk-covid-19-due-certain-variants-not-neutralized-evusheld?ref=fdaweb.com) detailed neutralization data can be found in the revised authorized [Fact Sheet for Healthcare Providers.](https://www.fda.gov/media/154701/download?ref=fdaweb.com) Health care professionals should inform patients of this risk and advise patients who develop symptoms to get tested for Covid-19\. The agency says that Evusheld remains the only option for pre-exposure prophylaxis of Covid-19 and is authorized for use in immunocompromised individuals who may not mount an adequate response to Covid-19 vaccination, and for individuals for whom Covid-19 vaccination is not recommended due to a history of a severe adverse reaction.